August 23, 2011
A large study by a team from the U.S. National Institutes of Health (NIH) finds the Cervarix human papillomavirus vaccine, which protects against cervical cancer caused by HPV, also offers strong protection against HPV-related anal cancer.
Cervarix targets HPV types 16 and 18, the strains most responsible for cervical cancer. These also "cause the bulk of anal cancers," explained study leader Dr. Aimee Kreimer of NIH's National Cancer Institute.
Researchers analyzed anal tissue specimens in a group of 4,210 healthy women ages 18-25 in Costa Rica. About half the women received Cervarix in three doses, and the other half received a placebo vaccine. After four years, the women were tested for anal and cervical HPV 16 and 18 infections.
08.22.2011; Julie Steenhuysen
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.